Recent News

• 11.19.2025 - OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference
• 11.19.2025 - OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference
• 10.29.2025 - OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results
• 10.29.2025 - OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results
• 10.29.2025 - OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications
• 10.29.2025 - OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications
• 10.28.2025 - OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers
• 10.28.2025 - OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers
• 10.22.2025 - OPKO Health to Report Third Quarter 2025 Financial Results on October 29
• 10.22.2025 - OPKO Health to Report Third Quarter 2025 Financial Results on October 29

Recent Filings

• 11.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.31.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.29.2025 - EX-99.1 EX-99.1
• 10.29.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 10.29.2025 - 8-K Current report
• 10.01.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 09.15.2025 - EX-99.1 EX-99.1
• 09.15.2025 - 8-K Current report